frince

About Frédéric Rince

This author has not yet filled in any details.
So far Frédéric Rince has created 543 blog entries.

EMA, NCI, and EORTC agree on first of its kind meeting: IBCD, Innovation and Biomarkers in Cancer Drug Development

The EORTC is proud to announce the signing of an agreement with the US National Cancer Institute (NCI), and the European Medicines Agency (EMA) to produce a first of its kind meeting to collaboratively explore current issues in cancer drug development. IBCD, Innovation and Biomarkers in Cancer Drug Development, will be held 3-4 December 2015 at the Square Brussels Meeting Centre and convene the multiple cancer research stakeholders needed for effective cancer drug development. 

By |2017-06-30T09:14:06+02:0012 Jan 2015||0 Comments
Read More

Leading European oncologists set sights on cancer clinical research issues

The new regulations “Regulation (EU) no 536/2014 of the European Parliament on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC” were published in April of this year.

By |2017-06-30T09:14:46+02:0010 Jan 2015||0 Comments
Read More

Breaking down the barriers to drug development

Dr. Francoise Meunier, EORTC Director General, Sir Michael Rawlins, former chair of NICE, and Robert Strieter, Novartis Institutes for Biomedical Research discuss translational medicine in respiratory disease in Prof. Peter Barnes’ latest instalment of ERS Vision. The film looks at ways to break down the barriers that obstruct and delay the development of new medicines at every stage of the discovery process.

By |2017-06-30T09:14:56+02:009 Jan 2015|, |0 Comments
Read More

EORTC trial to improve treatment for older patients with acute myeloid leukemia enrolls first patients

Intensive chemotherapy based on cytarabine combined with an anthracycline has a limited impact on the long-term overall survival for patients older than 60 years of age with acute myeloid leukemia (AML). Recently, though, encouraging results from a phase 2 trial investigating a 10-day decitabine schedule suggest that decitabine results in complete remission rates similar to those achieved with intensive chemotherapy with, however, less toxicity.

By |2014-12-16T16:49:44+01:0016 Dec 2014|, , , |0 Comments
Read More

EORTC’s Anastassia Negrouk speaks out on the EU Data Protection Regulation

Protection of privacy is a serious matter. However, in health research, straightening and narrowing participant’s consent or limiting data storage in time is unlikely to increase the level of protection. On the other hand, these measures would surely jeopardize health research and progress of medical science violating rights on adequate health care and freedom of research.

By |2014-12-15T12:31:45+01:0015 Dec 2014|, |0 Comments
Read More

Male and female breast cancers are not identical

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women. The study, which included 1822 men treated for breast cancer between 1990 and 2010, provides much needed information about the clinical and biological characteristics of male breast cancer.
 

By |2014-12-12T11:23:21+01:0012 Dec 2014|, , |2 Comments
Read More

New Data at ASH 2014 Highlight Progress of Pfizer’s Growing Portfolio in Blood Cancers

MYLOTARGTM (gemtuzumab ozogamicin) Demonstrates Promising Efficacy Across Multiple Phase 3 Studies in First-Line Acute Myeloid Leukemia (AML)1,2
-------------------------
Pfizer in Discussions with Regulators on Path Forward for MYLOTARG
-------------------------
New Long-Term, Follow-Up Data Show Chronic Myeloid Leukemia (CML) Patients Benefit from BOSULIF® (bosutinib) at 4 and 5 years3,4
-------------------------

By |2014-12-09T10:17:30+01:009 Dec 2014|, , |0 Comments
Read More

EORTC to study cancer diagnostic/treatment approaches in nursing homes with the support of Armonea

The EORTC, with the support of Armonea, has launched a study which includes translational research in order to improve prognostic tools and assist in making treatment decisions for elderly patients with cancer who live in nursing homes in Belgium within the Armonea network. This prospective observational study, EORTC 1221, is coordinated by the EORTC Cancer in Elderly Task Force.

By |2014-12-03T16:06:00+01:003 Dec 2014|, , |0 Comments
Read More

EORTC Medical Director Dr Vassilis Golfinopoulos talks about the aims of SPECTA

Hear EORTC Medical Director Dr Vassilis Golfinopoulos talk about the aims of SPECTA (Screening Patients for Efficient Clinical Trial Access) and catch up on other news from 26th EORTC - NCI - AACR symposium on molecular targets in cancer therapeutics in Barcelona.

By |2014-12-01T09:36:43+01:001 Dec 2014|, , , |0 Comments
Read More

Press releases from the 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics in Barcelona

The 26th EORTC - NCI - AACR symposium on molecular targets in cancer therapeutics recently held in Barcelona proved to be a very successful event. Below is a listing of some of the many results announced at this prestigious symposium:

Early results of new drug, ASP8273, show response in Japanese patients with treatment-resistant non-small cell lung cancer

By |2014-11-24T15:51:52+01:0024 Nov 2014|, |0 Comments
Read More
Go to Top